Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors

L. Porcelli, A. E. Quatrale, P. Mantuano, N. Silvestris, J. F. Rolland, L. Biancolillo, A. Paradiso, A. Azzariti

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Single-agent therapy with molecularly targeted agents has shown limited success in tumor growth control, mainly because escape or resistance mechanisms are activated once a signalling molecule is inhibited. Rational combinations of target-specific agents could counteract this response providing a useful strategy in cancer treatment. In this regard, the EGFR and mTOR inhibitors have been used together to generate a synergistic effect and maximize the efficacy of each individual agent. Overall, the in vivo and in vitro evidences support the utilization of combinations targeting EGFR and mTOR, for malignancies characterized by deregulated EGFR/PI3K/Akt/ mTOR signalling cascade; whereas the clinical experience points out that the assessment of the therapeutic value of such combination awaits further investigations.

Original languageEnglish
Pages (from-to)918-926
Number of pages9
JournalCurrent Pharmaceutical Design
Volume19
Issue number5
Publication statusPublished - 2013

Fingerprint

Neoplasms
Phosphatidylinositol 3-Kinases
Therapeutics
Growth
In Vitro Techniques

Keywords

  • Biomarkers
  • Clinical trials
  • Combination therapy
  • EGFR
  • mTOR

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Porcelli, L., Quatrale, A. E., Mantuano, P., Silvestris, N., Rolland, J. F., Biancolillo, L., ... Azzariti, A. (2013). Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors. Current Pharmaceutical Design, 19(5), 918-926.

Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors. / Porcelli, L.; Quatrale, A. E.; Mantuano, P.; Silvestris, N.; Rolland, J. F.; Biancolillo, L.; Paradiso, A.; Azzariti, A.

In: Current Pharmaceutical Design, Vol. 19, No. 5, 2013, p. 918-926.

Research output: Contribution to journalArticle

Porcelli, L, Quatrale, AE, Mantuano, P, Silvestris, N, Rolland, JF, Biancolillo, L, Paradiso, A & Azzariti, A 2013, 'Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors', Current Pharmaceutical Design, vol. 19, no. 5, pp. 918-926.
Porcelli L, Quatrale AE, Mantuano P, Silvestris N, Rolland JF, Biancolillo L et al. Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors. Current Pharmaceutical Design. 2013;19(5):918-926.
Porcelli, L. ; Quatrale, A. E. ; Mantuano, P. ; Silvestris, N. ; Rolland, J. F. ; Biancolillo, L. ; Paradiso, A. ; Azzariti, A. / Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors. In: Current Pharmaceutical Design. 2013 ; Vol. 19, No. 5. pp. 918-926.
@article{9df630a7a93d42fc890e29917ac469b5,
title = "Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors",
abstract = "Single-agent therapy with molecularly targeted agents has shown limited success in tumor growth control, mainly because escape or resistance mechanisms are activated once a signalling molecule is inhibited. Rational combinations of target-specific agents could counteract this response providing a useful strategy in cancer treatment. In this regard, the EGFR and mTOR inhibitors have been used together to generate a synergistic effect and maximize the efficacy of each individual agent. Overall, the in vivo and in vitro evidences support the utilization of combinations targeting EGFR and mTOR, for malignancies characterized by deregulated EGFR/PI3K/Akt/ mTOR signalling cascade; whereas the clinical experience points out that the assessment of the therapeutic value of such combination awaits further investigations.",
keywords = "Biomarkers, Clinical trials, Combination therapy, EGFR, mTOR",
author = "L. Porcelli and Quatrale, {A. E.} and P. Mantuano and N. Silvestris and Rolland, {J. F.} and L. Biancolillo and A. Paradiso and A. Azzariti",
year = "2013",
language = "English",
volume = "19",
pages = "918--926",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors

AU - Porcelli, L.

AU - Quatrale, A. E.

AU - Mantuano, P.

AU - Silvestris, N.

AU - Rolland, J. F.

AU - Biancolillo, L.

AU - Paradiso, A.

AU - Azzariti, A.

PY - 2013

Y1 - 2013

N2 - Single-agent therapy with molecularly targeted agents has shown limited success in tumor growth control, mainly because escape or resistance mechanisms are activated once a signalling molecule is inhibited. Rational combinations of target-specific agents could counteract this response providing a useful strategy in cancer treatment. In this regard, the EGFR and mTOR inhibitors have been used together to generate a synergistic effect and maximize the efficacy of each individual agent. Overall, the in vivo and in vitro evidences support the utilization of combinations targeting EGFR and mTOR, for malignancies characterized by deregulated EGFR/PI3K/Akt/ mTOR signalling cascade; whereas the clinical experience points out that the assessment of the therapeutic value of such combination awaits further investigations.

AB - Single-agent therapy with molecularly targeted agents has shown limited success in tumor growth control, mainly because escape or resistance mechanisms are activated once a signalling molecule is inhibited. Rational combinations of target-specific agents could counteract this response providing a useful strategy in cancer treatment. In this regard, the EGFR and mTOR inhibitors have been used together to generate a synergistic effect and maximize the efficacy of each individual agent. Overall, the in vivo and in vitro evidences support the utilization of combinations targeting EGFR and mTOR, for malignancies characterized by deregulated EGFR/PI3K/Akt/ mTOR signalling cascade; whereas the clinical experience points out that the assessment of the therapeutic value of such combination awaits further investigations.

KW - Biomarkers

KW - Clinical trials

KW - Combination therapy

KW - EGFR

KW - mTOR

UR - http://www.scopus.com/inward/record.url?scp=84876706418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876706418&partnerID=8YFLogxK

M3 - Article

C2 - 22973960

AN - SCOPUS:84876706418

VL - 19

SP - 918

EP - 926

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 5

ER -